We present a retrospective histopathological study that included a total of 22 endometrial
carcinomas, from patients that were operated in the Obstetrics and Gynecology Clinics of the …

BACKGROUND The aim of this study was to compare the concordance between
immunohistochemical (IHC) and biochemical (RIA) methods for determining hormone …

OBJECTIVES.: To determine if epigenetic interference can restore progesterone receptor-B
(PR-B) expression in PR-B negative endometrial adenocarcinoma cell lines, and to …

Progestin resistance limits the effectiveness of progestin therapy in endometrial carcinoma
for patients who desire to preserve fertility. To investigate the molecular mechanism of …

Endometrial cancer is the most common gynecologic malignancy and represents a major
health concern because overall five-year survival rates have not improved in the last three …

One hundred patients with Stage III and IV epithelial ovarian cancer participated in a
prospective randomized study to determine whether the addition of tamoxifen, an estrogen …

For several years it was generally believed that only a single estrogen receptor (ER) and
progesterone receptor (PR) existed. However, the discovery of a new ER (ERβ) with …

Objective. Tamoxifen is the most widely used antiestrogen to treat all stages of estrogen-
receptor (ER)-positive breast cancers. However, tamoxifen acts as a partial estrogen in the …

Estrogen and progesterone receptor concentrations were measured in the primary tumors of
137 surgically staged women with clinical stages I and II endometrial carcinoma. For each …

Human endometrial cancer expresses both the known estrogen receptors (ER-α and ER-β).
The significance of the relative expression of both ER subtypes in endometrial …